To access this element change to forms mode OFF
Grant Award View - GA30231
BCG+MM Trial: Adding mitomycin to BCG as adjuvant intravesical therapy...
GA ID:
GA30231
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
25-Oct-2018
Publish Date:
21-Dec-2018
Category:
Medical Research
Grant Term:
1-Jan-2019 to 31-Dec-2023
Value (AUD):
$1,587,163.80
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 17/18 1.1 Health and Medical Research
Grant Program:
Project
Grant Activity:
BCG+MM Trial: Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: a 2-stage, randomised phase 3 trial.
Purpose:
Non-muscle invasive bladder cancer is common, causes substantial suffering and requires radical removal or irradiation of the bladder within 5 years in over 30 percent of people with high risk tumours despite best current treatment. Preliminary studies show exciting results from adding mitomycin (a chemotherapy drug) to best current treatment with BCG (an immunotherapy). This large randomized trial will determine the effects of adding mitomycin on cure rates, survival, side effects and quality of life.
GO ID:
GO Title:
NHMRC Project Grant Scheme
Internal Reference ID:
GNT1159787
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Sydney
Recipient ABN:
15 211 513 464
Grant Recipient Location
Suburb:
Camperdown
Town/City:
Camperdown
Postcode:
2050
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW
Postcode:
Country:
AUSTRALIA